Literature DB >> 6090710

Varicella-zoster viral glycoproteins analyzed with monoclonal antibodies.

B Forghani, K W Dupuis, N J Schmidt.   

Abstract

Monoclonal antibodies to varicella-zoster virus were used to study viral glycoproteins by immunoprecipitation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Based on the viral glycoproteins immunoprecipitated, the five monoclonal antibodies fell into three groups. Two antibodies, 4B7 and 8G9 (group 1), immunoprecipitated a single glycoprotein of molecular weight (MW) 118,000 (118K glycoprotein) and had high neutralizing activity in the absence of complement. One antibody, 3C7 (group 2), which lacked neutralizing activity, immunoprecipitated two glycoproteins of MWs 120,000 and 118,000 and a glycoprotein giving a diffuse band in the region of 64,000 to 65,000. Pulse-chase experiments and experiments with monensin as an inhibitor of glycosylation suggested that the 120K polypeptide was derived by glycosylation of the 118K polypeptide and that a 43K antigen was processed into the 64 to 65K glycoprotein. Two antibodies, 3G8 and 4E6 (group 3), both had neutralizing activity only in the presence of complement, and both immunoprecipitated at least five polypeptides, with MWs ranging from 50,000 to 90,000. Antibody 3G8 was isotype immunoglobulin G2b (IgG2b), and its immunoprecipitating activity was stronger than that of 4E6, which was isotype IgG1. Pulse-chase experiments with antibody 3G8 showed that lower-MW glycopeptides chased into three polypeptides of MWs 90,000, 80,000, and 60,000 by 24 h. Immunoprecipitation experiments with antibody 3G8 on infected cells treated with glycosylation inhibitors 2-deoxyglucose, monensin, and tunicamycin, suggested that a prominent, early-appearing 70K polypeptide may have been processed into the glycoproteins of higher MWs and that the 60K polypeptide may have been derived by glycosylation of polypeptides of lower MWs.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6090710      PMCID: PMC254488     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Serological reactivity of some monoclonal antibodies to varicella-zoster virus.

Authors:  B Forghani; N J Schmidt; C K Myoraku; D Gallo
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

2.  Effect of tunicamycin on the synthesis of herpes simplex virus type 1 glycoproteins and their expression on the cell surface.

Authors:  B Norrild; B Pedersen
Journal:  J Virol       Date:  1982-08       Impact factor: 5.103

3.  Monensin inhibits the processing of herpes simplex virus glycoproteins, their transport to the cell surface, and the egress of virions from infected cells.

Authors:  D C Johnson; P G Spear
Journal:  J Virol       Date:  1982-09       Impact factor: 5.103

4.  Effect of the ionophore monensin on herpes simplex virus type 1-induced cell fusion, glycoprotein synthesis, and virion infectivity.

Authors:  K G Kousoulas; D J Bzik; S Person
Journal:  Intervirology       Date:  1983       Impact factor: 1.763

5.  Monoclonal antibodies against three major glycoproteins of varicella-zoster virus.

Authors:  C Grose; D P Edwards; W E Friedrichs; K A Weigle; W L McGuire
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

6.  Virus particles and glycoprotein excreted from cultured cells infected with varicella-zoster virus (VZV).

Authors:  K Shiraki; M Takahashi
Journal:  J Gen Virol       Date:  1982-08       Impact factor: 3.891

7.  Polypeptides of varicella-zoster virus (VZV) and immunological relationship of VZV and herpes simplex virus (HSV).

Authors:  K Shiraki; T Okuno; K Yamanishi; M Takahashi
Journal:  J Gen Virol       Date:  1982-08       Impact factor: 3.891

8.  Inhibition of glycosylation of herpes simplex virus glycoproteins: identification of antigenic and immunogenic partially glycosylated glycopeptides on the cell surface membrane.

Authors:  J Glorioso; M S Szczesiul; S D Marlin; M Levine
Journal:  Virology       Date:  1983-04-15       Impact factor: 3.616

9.  Common expression of varicella-zoster viral glycoprotein antigens in vitro and in chickenpox and zoster vesicles.

Authors:  K A Weigle; C Grose
Journal:  J Infect Dis       Date:  1983-10       Impact factor: 5.226

10.  Synthesis and processing of glycoproteins of Varicella-Zoster virus (VZV) as studied with monoclonal antibodies to VZV antigens.

Authors:  T Okuno; K Yamanishi; K Shiraki; M Takahashi
Journal:  Virology       Date:  1983-09       Impact factor: 3.616

View more
  17 in total

1.  Comparison of biotinylated DNA and RNA probes for rapid detection of varicella-zoster virus genome by in situ hybridization.

Authors:  B Forghani; G J Yu; J W Hurst
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

2.  Neutralizing antibodies specific for glycoprotein H of herpes simplex virus permit viral attachment to cells but prevent penetration.

Authors:  A O Fuller; R E Santos; P G Spear
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

3.  Cross-reactivity between herpes simplex virus glycoprotein B and a 63,000-dalton varicella-zoster virus envelope glycoprotein.

Authors:  C M Edson; B A Hosler; R A Respess; D J Waters; D A Thorley-Lawson
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

4.  Transcription mapping of the varicella-zoster virus genome.

Authors:  J M Ostrove; W Reinhold; C M Fan; S Zorn; J Hay; S E Straus
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103

5.  Varicella-zoster virus (VZV) transcription during latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA.

Authors:  R J Cohrs; M Barbour; D H Gilden
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

6.  Assembly and processing of the disulfide-linked varicella-zoster virus glycoprotein gpII(140).

Authors:  E A Montalvo; C Grose
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

7.  Varicella-zoster virus (VZV) transcription during latency in human ganglia: construction of a cDNA library from latently infected human trigeminal ganglia and detection of a VZV transcript.

Authors:  R J Cohrs; K Srock; M B Barbour; G Owens; R Mahalingam; M E Devlin; M Wellish; D H Gilden
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

8.  Neutralizing antibodies induced by recombinant vaccinia virus expressing varicella-zoster virus gpIV.

Authors:  A Vafai; W N Yang
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

9.  Characterization and immunogenicity of a candidate subunit vaccine against varicella-zoster virus.

Authors:  J Davies; J A Hallworth; P McLeish; S Randall; B A Martin; A Buchan; G R Skinner
Journal:  Med Microbiol Immunol       Date:  1994-05       Impact factor: 3.402

10.  Comparative immunohistochemical study of herpes simplex and varicella-zoster infections.

Authors:  A F Nikkels; S Debrus; C Sadzot-Delvaux; J Piette; P Delvenne; B Rentier; G E Piérard
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.